Vaccine could offer protection against ear infections

by David Stacey
Vaccine could offer protection against ear infections

A team of international researchers has moved a step closer to developing a vaccine to protect against middle ear infection, currently the most common infection in children under the age of five. The vaccine could also be used for those with poor lung function, such as cystic fibrosis sufferers.

Assistant Professor Tim Perkins, from UWA's School of Pathology and Laboratory Medicine, was part of the research team that studied a diverse collection of strains of the bacterial species Haemophilus influenzae, which causes most middle ear infections as well as meningitis.

Professor Perkins said vaccines were the cheapest preventable medicine available for infectious diseases and the development of a vaccine would benefit children and reduce the cost of treating infections which currently cost $380 million per year in Australia alone.

"Not only would a vaccine reduce the incidence of disease in children, it would increase the productivity of working parents and result in fewer GP visits and antibiotic prescriptions," he said.

Professor Perkins said meningitis, middle ear and lung infections could be caused by a wide variety of and while vaccines were available for most meningitis infections caused by bacteria, there was no vaccine for , which affected so many young children.

"Bacteria often protect themselves with a sugar-like capsule and very often the presence of such a structure is the main reason the bacteria can cause disease. Haemophilus influenzae protects itself with a capsule and this structure has been successfully incorporated into a vaccine to induce protection against such bacteria.

"However, there are bacteria from the same species that are not encapsulated (i.e. the vaccine will not protect against these strains) and they are often associated with causing infections in children and in people with poor lung function."

To understand if an alternative part of the bacteria's structure could be used to create a vaccine to protect against these strains the researchers analysed the genome of nearly 100 different strains from different parts of the world.

The study characterised a diverse collection of strains from throughout the world and a few components were always found in each strain, he said. These components were also found on the surface of the bacteria and were most likely to interact with human cells, making them ideal to test in new formulations.

add to favorites email to friend print save as pdf

Related Stories

Booster dose of new meningitis vaccine may be beneficial

Sep 23, 2013

A study of 4CMenB, a new vaccine to protect against meningitis B bacteria (which can cause potentially fatal bacterial meningitis in children), shows that waning immunity induced by infant vaccination can be overcome by a ...

Study finds Pfizer vaccine cuts pneumonia in elderly

Mar 12, 2014

Pfizer Inc. said Wednesday that its blockbuster vaccine against pneumonia, blood and other infections met its goal of preventing illness in vulnerable elderly patients in a huge study required by U.S. regulators.

Recommended for you

Where Ebola battles are won

8 hours ago

(HealthDay)—Four hospitals that are home to advanced biocontainment facilities have become America's ground zero in the treatment of Ebola patients.

Depression tied to worse lumbar spine surgery outcomes

10 hours ago

(HealthDay)—Depressive symptoms are associated with poorer long-term outcome in patients undergoing surgery for lumbar spinal stenosis (LSS), according to research published in the Oct. 1 issue of The Sp ...

Ebola death toll edging to 4,900 mark: WHO

11 hours ago

The death toll in the world's worst-ever Ebola outbreak has edged closer to 4,900, while almost 10,000 people have now been infected, new figures from the World Health Organization showed Wednesday.

US to track everyone coming from Ebola nations

11 hours ago

U.S. authorities said Wednesday that everyone traveling into the U.S. from Ebola-stricken nations will be monitored for symptoms for 21 days. That includes returning American aid workers, federal health employees ...

User comments